COX-2 Inhibition Potentiates Antiangiogenic Cancer Therapy and Prevents Metastasis in Preclinical Models

@article{Xu2014COX2IP,
  title={COX-2 Inhibition Potentiates Antiangiogenic Cancer Therapy and Prevents Metastasis in Preclinical Models},
  author={Ling Xu and Janine Stevens and Mary Beth Hilton and Steven Seaman and Thomas P. Conrads and Timothy D. Veenstra and Daniel Logsdon and Holly Morris and Deborah A. Swing and Nimit L. Patel and Joseph D. Kalen and Diana C. Haines and Enrique Zudaire and Brad St. Croix},
  journal={Science Translational Medicine},
  year={2014},
  volume={6},
  pages={242ra84-242ra84}
}
Antiangiogenic agents that block vascular endothelial growth factor (VEGF) signaling are important components of current cancer treatment modalities but are limited by alternative ill-defined angiogenesis mechanisms that allow persistent tumor vascularization in the face of continued VEGF pathway blockade. We identified prostaglandin E2 (PGE2) as a soluble tumor-derived angiogenic factor associated with VEGF-independent angiogenesis. PGE2 production in preclinical breast and colon cancer models… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 6 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Impact on invasion, disease progression, and metastasis

J. M. Ebos, R. S. Kerbel, Antiangiogenic therapy
Nat. Rev. Clin. Oncol. 8, 210–221 • 2011
View 5 Excerpts
Highly Influenced

Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2013

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

The New England journal of medicine • 2012
View 1 Excerpt

What next? J

E. Van Cutsem, D. Lambrechts, +3 authors Lessons from the adjuvant bevacizumab trial on colon cancer
Clin. Oncol. 29, 1–4 • 2011

Challenges and rationale

A. Bagri, H. Kouros-Mehr, K. G. Leong, G. D. Plowman, Use of anti-VEGF adjuvant therapy in cancer
Trends Mol. Med. 16, 122–132 • 2010
View 1 Excerpt

Similar Papers

Loading similar papers…